Skip to main content
Caplight Logo









PersonGen BioTherapeutics

PersonGen BioTherapeutics

Private
SuzhouHealthcare & Life Scienceshttps://persongen.com/

Last Round

Series B

Jan 1, 2022

Total Funding Raised

$51.6M

Company Overview

PersonGen BioTherapeutics is a biotechnology company that develops innovative cellular immunotherapies, including CAR-T cell therapies, for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cellular immunotherapyCAR-T therapyallogeneic cell therapyoff-the-shelf CAR-Tcell therapy platformin-vivo cell engineeringuniversal CAR-TCD7-targeted therapyhematological malignanciessolid tumor treatmentnext-gen immunotherapyGMP manufacturingexosome preparationautoimmune disease therapybiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PersonGen BioTherapeutics Comparables

Compare PersonGen BioTherapeutics with similar companies based on industry and business-model similarity.

PersonGen BioTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hebei Senlang Biotechnology Co., Ltd.
88%
Juventas Cell Therapy Ltd.
86%
AbelZeta Pharma
84%

PersonGen BioTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 1, 2022
Series AMay 1, 2021
StrategicNov 11, 2015
AngelAug 1, 2012

PersonGen BioTherapeutics Investors

Notable investors and investment history

PersonGen BioTherapeutics investors
InvestorRounds
Shenzhen Sangel Venture CapitalSeries A
YuanBio Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2025

    Monthly visitors grew 2789% MoM to 1.3K.

  • Jan 1, 2022

    $31M round led by Nanjing Huatai Guoxin and China Kim Kaide.

PersonGen BioTherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PersonGen BioTherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PersonGen BioTherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Year Founded2010
Last FundingJan 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?